1. Paper › Research › Not peer-reviewed
2. Published

   Public funding of drugs for orphan diseases

   Hughes, D. & Hughes, D. A., 1 Nov 2005.

   Research output: Contribution to conference › Paper

3. Published

   Public meetings of the NICE appraisals committee

   Hughes, D. & Hughes, D. A., 1 Dec 2007.

   Research output: Contribution to conference › Paper

4. Published

   Quantitative risk-benefit analysis

   Hughes, D. & Hughes, D. A., 1 May 2007.

   Research output: Contribution to conference › Paper

5. Published

   Rationing of drugs for rare diseases

   Hughes, D. & Hughes, D. A., 1 Apr 2006.

   Research output: Contribution to conference › Paper

6. Published

   Systematic review of follow-up of cancer in primary care verses secondary care: findings for breast and lung cancer

   Hughes, D., Lewis, R., Neal, R. D., France, B., Williams, N. H., Wilkinson, C., Russell, I. T., Russell, D., Hughes, D. A., Stuart, N. S. & Weller, D., 1 Mar 2007.

   Research output: Contribution to conference › Paper

7. Published

   The all wales medicines strategy group: assessments and appraisals

   Hughes, D. & Hughes, D. A., 1 Nov 2008.

   Research output: Contribution to conference › Paper

8. Published

   The assessment, determinants & economics of medication compliance & persistence

   Hughes, D., Hughes, D. A., Gwadry Sridhar, F. & Elliott, R., 1 Oct 2007.

   Research output: Contribution to conference › Paper

9. Published

   The cost-effectiveness of biological therapies for Crohn's disease: Markov cohort analyses incorporating UK patient-level cost data

   Hughes, D., Bodger, K., Kikuchi, T. & Hughes, D. A., 1 Mar 2008.

   Research output: Contribution to conference › Paper

10. Published

    The cost-effectiveness of biological therapies for Crohn's disease: markov cohot analyses incorporating UK patient-level cost data

    Hughes, D., Hughes, D. A., Bodger, K. & Kikuchi, T., 1 May 2008.

    Research output: Contribution to conference › Paper

11. Published

    The economics of evergreening.

    Hughes, D. & Hughes, D. A., 1 Jan 2009.

    Research output: Contribution to conference › Paper

12. Published

    The effect of compliance upon clinical effectiveness of chlorproguanil-dapsone (CD) and artemether-lumefantrine (AL) when compared to sulfadoxine-pyrimethamine (SP) for the treatment of uncomplicated falcipaum malaria in Malawi - a randomised controlled trial

    Hughes, D., Bell, D. J., Wootton, D., Mukaka, M., Montgomery, J., Kayange, N., Chimpeni, P., Zijlstra, E., Hughes D.A., [. V., Molyneux M.E.*, [. V., Ward, S. A., Winstanley, P. A. & Lalloo, D. G., 1 Nov 2007.

    Research output: Contribution to conference › Paper

13. Published

    The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies

    Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Nov 2000.

    Research output: Contribution to conference › Paper

14. Published

    The pharmacokinetic profile of Warfarn: a systematic review

    Hughes, D., Al-Zubiedi S.*, [. V., Hughes D.A., [. V. & Pirmohamed, M., 1 Dec 2007.

    Research output: Contribution to conference › Paper

15. Published

    The population pharmacokinetics of lapdap

    Hughes, D., Ward, S., Simpson, J., Aarons, L., Szwandt, S. & Hughes, D. A., 1 Nov 2002.

    Research output: Contribution to conference › Paper

16. Published

    Ultra-long acting pharmaceuticals: Do they result in better outcomes, and at an acceptable cost?

    Hughes, D. & Hughes, D. A., 1 Nov 2006.

    Research output: Contribution to conference › Paper

17. Published

    Use of PK-PD modelling to predict the impact of non-compliance

    Hughes, D. & Hughes, D. A., 1 Nov 2003.

    Research output: Contribution to conference › Paper

18. Published

    What determines which interventions improve compliance, and do they improve health outcomes in a cost-effective manner?

    Hughes, D., Hughes, D. A., LaFleur.*, [. V., Salas, M. & Shinogle, J., 1 May 2007.

    Research output: Contribution to conference › Paper

19. Paper › Research › Peer-reviewed
20. Published

    A Systematic Review of Patient Preferences for Subcutaneous Medications

    Ridyard, C., Dawoud, D. & Hughes, D., Nov 2013.

    Research output: Contribution to conference › Paper › peer-review

21. Published

    Identification Of Items For A Standardised Resource-Use Measure: Review Of Current Instruments

    Thorn, J. C., Ridyard, C., Riley, R., Brookes, S., Hughes, D., Wordsworth, S., Noble, S. & Hollingworth, W., Nov 2015.

    Research output: Contribution to conference › Paper › peer-review

22. Published

    Review of the Use of Resource Use Instruments Based on Patient Recall in Relation to Other Methods of Cost Estimation

    Ridyard, C. & Hughes, D., Nov 2013.

    Research output: Contribution to conference › Paper › peer-review

23. Published

    Review of the use of resource use instruments based on patient recall in relation to other methods of resource use estimation

    Ridyard, C. & Hughes, D., Nov 2013.

    Research output: Contribution to conference › Paper › peer-review

24. Published

    Screening log data can be used to inform protocol modifications, increasing patient recrutiment to a challanging clinical trial

    Blair, J., Awoyale, L., Thornborough, K., Peak, M., Didi, M., Bedson, E., Hughes, D., Ridyard, C., Tat, T. & Gregory, J., Nov 2013.

    Research output: Contribution to conference › Paper › peer-review

25. Poster › Research › Peer-reviewed
26. Published

    Carer-administration of as-needed sub-cutaneous medication for breakthrough symptoms in homebased dying patients: a UK study (CARIAD)

    Wilkinson, C., Poolman, M., Roberts, J., Wee, B., Hiscock, J., Hughes, D., Nelson, A., Perkins, P., Johnstone, R. P., Reymond, E., Foster, B., O'Connor, J., Jones, S., Hoare, Z., Roberts, R., Byrne, A., Healy, S. & Lewis, P., 1 Sept 2017.

    Research output: Contribution to conference › Poster › peer-review

27. Published

    Comparison of regression methods for the cost effectiveness analysis of clinical trials with a small population size: the sycamore and folated trials

    Culeddu, G., Hughes, D. & Welton, N., 10 Jul 2017.

    Research output: Contribution to conference › Poster › peer-review

28. Published

    Core items for a standardised resource-use measure (ISRUM):expert Delphi consensus survey

    Thorn, J., Ridyard, C., Riley, R., Brookes, S., Hughes, D., Wordsworth, S., Noble, S., Thornton, G. & Hollingworth, W., 7 May 2017, p. P265. 1 p.

    Research output: Contribution to conference › Poster › peer-review

29. Published

    Health Economics Analysis Plans: Where Are We Now?

    Thorn, J., Ridyard, C., Hughes, D., Wordsworth, S., Mihaylova, B., Noble, S. & Hollingworth, W., 3 Nov 2016, p. A397. 1 p.

    Research output: Contribution to conference › Poster › peer-review

30. Published

    Health economics analysis plans: the current state of play

    Thorn, J., Ridyard, C., Hughes, D., Wordsworth, S., Mihaylova, B., Noble, S. & Hollingworth, W., 7 May 2017, p. P144. 1 p.

    Research output: Contribution to conference › Poster › peer-review

31. Published

    Patient-level information and costing systems (PLICS) as a source of routinely collected cost data for trial-based economic evaluations

    Ridyard, C. & Hughes, D., 7 May 2017, p. P141. 1 p.

    Research output: Contribution to conference › Poster › peer-review

32. Abstract › Research › Peer-reviewed
33. Published

    Continuous subcutaneous insulin infusion compated to multiple daily injection regimens in children and yung people at diagnosis of type 1 diabetes: A pragmatic randomised controlled trial and economic evaluation (scipi trial)

    Blair, J., Mckay, A., Ridyard, C., Thornborough, K., Bedson, E., Peak, M., Didi, M., Annan, F., John, G., Hughes, D. & Gamble, C., Sept 2017, p. 22-23.

    Research output: Contribution to conference › Abstract › peer-review

34. Other › Research › Peer-reviewed
35. Published

    Cost-Effectiveness Analysis of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa

    Culeddu, G., Brogan, P. A. & Hughes, D., 2021.

    Research output: Contribution to conference › Other › peer-review

36. Commissioned report › Research › Not peer-reviewed
37. Published

    A review of economic models for second-line chemotherapy in the management of advanced, metastatic breast cancer.

    Hughes, D. & Hughes, D. A., 1 Jan 2001, 2001 ed. Unknown.

    Research output: Book/Report › Commissioned report

38. Published

    AWMSG criteria for appraising new medicines.

    Hughes, D. & Hughes, D. A., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

39. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

40. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

41. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Ambrisentan (Volibris) for pulmonary arterial hypertension.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2009, 2009 ed. Unknown.

    Research output: Book/Report › Commissioned report

42. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2009, 2009 ed. Unknown.

    Research output: Book/Report › Commissioned report

43. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

44. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

45. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Buprenorphine/naloxone (Suboxone) as substitution treatment for opioid dependence.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

46. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

47. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Docetaxel (Taxotere) for locally advanced squamous cell carcinoma of the head and neck.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

48. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

49. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Epoetin delta (Dynepo)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

50. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for STEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

51. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for UA/NSTEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

52. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

53. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Lenalidomide (Revlimid) for multiple myeloma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

54. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Maraviroc (Celsentri) for treatment-experienced adults infected only with CCR5-tropic HIV-1.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2009, 2009 ed. Unknown.

    Research output: Book/Report › Commissioned report

55. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Pegfilgrastim (Neulasta) for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

56. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Raltegravir (Isentress) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report